Nathan Dolloff, Ph.D.
Discovering small molecules and biologics (recombinant protein therapeutics, monoclonal and bispecific antibodies) that serve as tools to interrogate new mechanisms in cancer biology and as potential drug candidates for future development.
Research Interest
I am a cancer researcher with expertise in experimental cancer therapeutics, high throughput drug screening (HTS), academic drug discovery, preclinical drug development, and faculty entrepreneurship. I have led projects that have delivered small molecules and monoclonal antibodies targeting alpha-PDGFR (olaratumab/LARTRUVO), dual inhibitors of GSK-3beta and CDK1, CDK9, and protein disulfide isomerase (PDI). A general approach of my lab is to identify and target mechanisms of resistance to cancer therapy. Projects have included targeting mechanisms of hypoxia-induced resistance, TRAIL resistance, proteasome inhibitor resistance in multiple myeloma, and the widespread resistance of cancer cells to epigenetic drugs. More recent efforts include developing new approaches to treat cancers that are considered immunologically “cold” and resistant to immunotherapy drugs. I am the Director of Entrepreneurship for the MUSC Hollings Cancer Center and MUSC Office of Innovation. In this role I promote the fundamental importance of commercialization and faculty entrepreneurship to the success of academic research programs.